


# Road to Replenishment

BOARD MEETING

**Marie-Ange Saraka-Yao**

6-7 December 2023, Accra, Ghana


# Gavi 5.1 resources are planned to be utilised



\* Does not sum due to rounding

# COVAX AMC funds proposals for reallocation

COVAX AMC Cash Balance vs v21 Forecast  
30 Sept 2023 to 31 Dec 2025  
in US\$ billions



1 Day Zero Financing Facility First Response Window and Coalition of Vaccine Partners  
2 Distribution of funds between PVP, ancillary and earned interest incomes might change pending finalisation of reallocations for each donor.

Board Meeting, 6-7 December 2023

## Headlines and next steps:

① Board approved up to US\$ 813 million from the COVAX AMC for a new programme for COVID-19 in 2024 and 2025 in June 2023.

After funding COVID-19 programme, **COVAX AMC balance is US\$ 2.9 billion**

② Per the June 2023 Board Decision:  
- that the **AMC Investors Group** consider funding options for use of the **COVAX AMC (PVP)** funding and the **Programme and Policy Committee (PPC)** consider the **programmatic perspective**

- The Board is requested to make decisions to reallocate funds COVAX AMC funds for **AVMA (African Vaccine Manufacturing Accelerator)**, the **Day Zero Financing Facility**, the **Coalition of Vaccine Partners plan** and the **Big Catch up**

Donors are **confirming the individual reallocation of their remaining COVAX AMC Funds** and will be processing the necessary amendments to their grant agreements, as relevant, contingent on Board approval on those investments.

③ A **COVAX AMC evaluation will be conducted in 2024**, after which COVAX AMC donors can decide to terminate the COVAX AMC at the end of 2025.

# Gavi can make decisive progress towards Sustainable Development Goal 3 before 2030



**Extending the power of existing vaccines including against human papillomavirus (HPV)** so that women are protected against cervical cancer.



**Introducing new powerful vaccines, including hexavalent** as an alternative to pentavalent and **malaria vaccine** to tackle one of the biggest killer of children in Africa.



**Extending routine protection against polio** to insure the world against polio re-emergence.



**Reaching children currently unprotected.** This improved protection is driving an increase in cost as volumes increase and new vaccines are at least initially more expensive.



**Fighting outbreaks and prevent and prepare for the next pandemic.**

# Gavi 6.0 replenishment timeline

Gavi 6.0 consultations with Board / PPC members, Alliance partners, countries, Global Health community


Gavi 6.0 strategy design

- 1 Trends, Gavi 6.0 vision & high-level opportunities for impact
- 2 Strategic options and initial trade-offs
- 3 Finalise choices and 'one-pager' framework

Gavi 6.0 operationalisation


Resource Mobilisation process

- 1 Listening phase & consultations
- 2 Drafting of the Investment Case
- 3 Public campaign



Board Meeting, 6-7 December 2023

# Towards Gavi 6.0 funding – Global Vaccine Summit (GVS) pledges vs today and potential Pandemic Vaccine Pool investments



# Thank you